

Iron Deficiency Anaemia but Why?

Dr LAU Ching-wa

Specialist in Haematology

Blood Transfusion Service


3 Questions

- 1. Is anaemia incurable in my patient?**
- 2. Is anaemia unavoidable in my bleeding patient?**
- 3. Is transfusion improved clinical outcomes in this particular clinical scenario?**

Iron Distribution

Total Body Iron
~ 50mg/kg BW

3000~
4000mg



Blood Volume
~ 75ml/kg BW

2200~
2600mg



Total Iron in RBC
1ml blood ≈ 0.5mg elemental Iron


Myoglobin & Iron – containing Enzymes

300~
400mg



Average Store
~10mg/kg

500~
1000mg



Total Body Iron
~ 40mg/kg BW

2000~
3000mg




Blood Volume
~ 65ml/kg BW

1300~
1950mg




Average Store
5-10mg/kg

400~
600mg



Iron Homeostasis

Iron cycle



Absolute Iron Deficiency

1. Inadequate Iron Absorption
2. Blood Loss

*(1ml blood \approx 0.5mg elemental Iron
 \downarrow 1g/dl Hb \approx 200mg elemental Iron loss)*




Figure 1. The role of hepcidin in iron metabolism. Hepcidin-ferroportin interaction determines the flow of iron into plasma. Hepcidin concentration is in turn regulated by iron, erythropoietic activity, and inflammation.⁶

“Relative” Iron Deficiency

- Fail to Mobilize Iron Store
- Anaemia of Chronic Illness

Underdiagnosed Anaemia Being Screened During First-time Blood Donation (Aged 16~65)

Proportion of Chinese First Time Donor who Failed Pre-donation Hemoglobin Check (2016 & 2017)											
Age Group	Men (Cut-off Hb < 13.0 g/dL)					Women (Cut-off Hb < 11.5 g/dL)					Overall Anaemia in Both Sexes
	Total No. of New Donors	Overall Anaemia in Men, n (%)	Mild Anaemia (Hb 11.0-12.9 g/dL)	Moderate Anaemia (Hb 8.0-10.9 g/dL)	Severe Anaemia (Hb < 8.0 g/dL)	Total No. of New Donors	Overall Anaemia in Women, n (%)	Mild Anaemia (Hb 11.0-11.4 g/dL)	Moderate Anaemia (Hb 8.0-10.9 g/dL)	Severe Anaemia (Hb < 8.0 g/dL)	
16-20	20069	1066 (5.3%)	1022 (5.1%)	43 (0.2%)	1 (0.0%)	27568	3379 (12.3%)	1542 (5.6%)	1789 (6.5%)	48 (0.2%)	4445 (9.3%)
21-30	10147	533 (5.3%)	515 (5.1%)	18 (0.2%)	0 (0.0%)	11316	1368 (12.1%)	626 (5.5%)	723 (6.4%)	19 (0.2%)	1901 (8.9%)
31-40	5309	262 (4.9%)	256 (4.8%)	6 (0.1%)	0 (0.0%)	8640	1199 (13.9%)	501 (5.8%)	675 (7.8%)	23 (0.3%)	1461 (10.5%)
41-50	3447	248 (7.2%)	238 (6.9%)	10 (0.3%)	0 (0.0%)	6475	1109 (17.1%)	422 (6.5%)	650 (10.0%)	37 (0.6%)	1357 (13.7%)
51-60	1874	158 (8.4%)	150 (8.0%)	8 (0.4%)	0 (0.0%)	3160	284 (9.0%)	155 (4.9%)	124 (3.9%)	5 (0.2%)	442 (8.8%)
61-65	93	11 (11.8%)	10 (10.8%)	1 (1.0%)	0 (0.0%)	116	10 (8.6%)	7 (6.0%)	3 (2.6%)	0 (0.0%)	21 (10.1%)
Total	40939	2281 (5.6%)	2194 (5.4%)	86 (0.2%)	1 (0.0%)	57312	7352 (12.8%)	3254 (5.7%)	3966 (6.9%)	132 (0.2%)	9633 (9.8%)

Another Study of Successful First-time Donors

Female: 32.4% have serum ferritin level below 30ng/ml &

19.6% have serum ferritin level below 15ng/ml (n=102).

Male: 1% have serum ferritin level below 30ng/ml (n=104).

Ferritin 1ng/mL ≈ 8mg Iron Store

Remark:

WHO Definition of Anaemia in Women 12.0g/dL

BTS Blood Donation Cutoff for Women: 11.5g/dL

Projected Overall Underdiagnosed Anaemia in the Society (Aged 16~65)

Data projected from Proportion of Low Hb Deferral of New Blood Donors 2016 to 2017
and Population Census data in 2017

Age group	Men					Women					Both Sexes				
	Mild Anaemia (Hb 11-12.9 g/dL)	Moderate Anaemia (Hb 8.0-10.9 g/dL)	Severe Anaemia (Hb<8.0 g/dL)	Overall Anaemia in Men	Overall Anaemia in Men %	Mild Anaemia (Hb 11-11.5 g/dL)	Moderate Anaemia (Hb 8.0-10.9 g/dL)	Severe Anaemia (Hb<8.0 g/dL)	Overall Anaemia in Women	Overall Anaemia in Women %	Mild (Hb 11 to 11.5 for female & 11 to 12.9g/dL for male)	Moderate (Hb 8 to 10.9g/dL)	Severe (Hb<8 g/dL)	Overall Anaemia in both sexes	Overall Anaemia in both sexes %
16-20	8173	344	8	8525	5.3%	8373	9715	261	18349	12.3%	16547	10059	269	26874	8.7%
21-30	22306	780	0	23086	5.3%	27190	31403	825	59418	12.1%	49496	32182	825	82504	8.9%
31-40	22292	522	0	22815	4.9%	40306	54305	1850	96461	13.9%	62598	54827	1850	119276	10.3%
41-50	32797	1378	0	34175	7.2%	43732	67359	3834	114925	17.1%	76528	68737	3834	149100	13.0%
51-60	47345	2525	0	49870	8.4%	32751	26201	1056	60008	9.0%	80096	28726	1056	109879	8.7%
61-65	27839	2784	0	30623	11.8%	16016	6864	0	22879	8.6%	43854	9648	0	53502	10.2%
Total	160752	8333	8	169093	7.1%	168367	195846	7827	372040	12.7%	329120	204179	7835	541134	10.2%

A portion of the mild anaemia may be related to thalassemia.


However, moderate and severe anaemia can seldom be explained by thalassemia.

Remark:

WHO Definition of Anaemia in Women $\leq 12.0\text{g/dL}$

BTS Blood Donation Cutoff for Women: 11.5g/dL

Indications of Blood Transfusion in 2016



- Blood Loss (Gynecology 4%, GIB 20%, Elective operations 13%, Emergency operations 8%, Trauma 5%)
- Renal Insufficiency (Hemodialysis 7%, peritoneal dialysis and non-dialysis 7%)
- Marrow Failure 10%, Red Cell Disorders 6%, Hematological Malignancy 10%, some Oncological conditions 10%

Perpetuation of Iron Deficiency

Hospital Settings:

- Blood Transfusion as reflex response to treat Anaemia
- Pathological causes of Blood Loss managed
- Under-diagnosed Iron Deficiency in many chronic illness e.g. Chronic Renal Impairment, Chronic Heart Failure, Malignancy, Inflammatory Conditions...
- Blood Loss due to various procedures and blood taking
- Insufficient treatment to minimize Blood Loss
- Underlying Iron Deficiency seldom received adequate treatment



GP/FM/SOPD Settings:

- Pathological causes of Blood Loss diagnosed and treated *or* referred to Hospital
- Underlying Iron Deficiency seldom received adequate treatment
- Insufficient treatment to control chronic Blood Loss (physiological or pathological)
- Anti-platelet or oral anti-coagulation therapy may increase Blood Loss
- Acid suppressants inhibit Iron Absorption



Iron Deficiency related to:

- Inadequate Iron Intake
- Suboptimal Iron Absorption
- Helicobacter Pylori Infection
- Physiological Blood Loss
- Suboptimal Iron Supplement during pregnancy
- Blood Donation
- Poor Compliance to Iron Therapy



1. Inadequate Iron Intake

**>80% of the male population &
>90% of the female population below the
recommended nutrient intake level for iron for adult**



*Centre for Food Safety of the Food and Environmental Hygiene Department
2014*



The recommended nutrient intakes for iron based on varying dietary iron bio-availabilities

Group	Age (years)	Mean Body weight (kg)	Recommended Nutrient Intake (mg/day)			
			% Dietary Iron Bio-availability			
			15	12	10	5
Children	0.5-1	9	[6.2] ^b	[7.7] ^b	[9.3] ^b	[18.6] ^b
	1-3	13.3	3.9	4.8	5.8	11.6
	4-6	19.2	4.2	5.3	6.3	12.6
	7-10	28.1	5.9	7.4	8.9	17.8
Males	11-14	45	9.7	12.2	14.6	29.2
	15-17	64.4	12.5	15.7	18.8	37.6
	18+	75	9.1	11.4	13.7	27.4
Females	11-14 ^c	46.1	9.3	11.7	14	28
	11-14	46.1	21.8	27.7	32.7	65.4
	15-17	56.4	20.7	25.8	31	62
	18+	62	19.6	24.5	29.4	58.8
Post-menopausal		62	7.5	9.4	11.3	22.6
Lactating		62	10	12.5	15	30

^aBased in part on a 1988 report from the FAO/WHO (8) and in part on new requirements in menstruating women. Because of the very skewed distribution of iron requirements are calculated for four levels of dietary iron bio-availability.

^bBio-availability of dietary iron during this period varies greatly.

^cNon-menstruating.

100克食物鐵質含量 (毫克) Iron (mg) Value per 100 g		100克食物鐵質含量 (毫克) Iron (mg) Value per 100 g	
肉類及家禽類		魚類及海產類	
牛肉 (熟) Beef (cooked)	2.6	八爪魚 (熟) Octopus (cooked)	9.5
羊肉 (熟) Lamb (cooked)	1.9	蜆 (熟) Oyster (cooked)	7
豬肉 (熟) Pork (cooked)	1.8	青口 (熟) Mussel (cooked)	6.7
雞肉 (熟) Chicken (cooked)	1.2	蜆 (熟) clam (cooked)	2.8
堅果及種子類		罐頭水浸吞拿魚 tuna, canned in oil	1.5
芝麻 Sesame	14.6	豆類	
葵花子 sunflower seeds	6.8	黃豆 (熟) soybean (cooked)	5.1
腰果 Cashew nuts	6	扁豆 (熟) Lentils (cooked)	3.3
開心果 pistachio	4	紅腰豆 (熟) Red Kidney Bean (cooked)	2.9
杏仁 Almond	3.7	雞心豆 (熟) chickpea (cooked)	2.9
核桃 Walnut	2.9	紅豆 (熟) Red Bean (cooked)	2
花生 Peanut	1.6	綠豆 (熟) Green Bean (cooked)	1.8
水果類		硬豆腐 (未煮) Firm Tofu	2.7
杞子乾 Dried Goji berries	6.8	蔬菜類	
杏脯乾 Dried Apricots	2.7	木耳 (乾) Dried Black Fungus	43.8
提子乾 Dried Raisins	2.6	菠菜 (熟) spinach (cooked)	3.6
		莧菜 (熟) Amaranth (cooked)	2.3
		紅菜頭 (熟) Beetroot (cooked)	1.8

2. Food Interaction affecting Heme Iron Absorption

- | | |
|---|---|
| 1 | Iron status of subject (The absorption of heme iron can vary from >40% during iron deficiency to about 10% during iron repletion) |
| 2 | Amount of dietary heme iron |
| 3 | Content of calcium in meal (e.g., milk, cheese) (Calcium is the only dietary factor that negatively influences the absorption of heme iron and does so to the same extent that it influences non-heme iron) |
| 4 | Food preparation (time, temperature) (Heme iron can be degraded and converted to non-heme iron if foods are cooked at a high temperature for too long) |

3. Food Interaction affecting non-Heme Iron Absorption

Enhancing factors	Inhibiting factors
Ascorbic acid (e.g., certain fruit juices, fruits, potatoes, and certain vegetables)	Phytates and other inositol phosphates (e.g., bran products, bread made from high-extraction flour, breakfast cereals, oats, rice [especially unpolished rice], pasta products, cocoa, nuts, soya beans, and peas)
Meat, chicken, fish and other seafood	Iron-binding phenolic compounds (e.g., tea, coffee, cocoa, certain spices, certain vegetables, and most red wines)
Fermented vegetables (e.g., sauerkraut), fermented soy sauces , etc.	Calcium (e.g., milk, cheese, soy proteins)

4. Helicobacter Pylori

- 58.4% population is infected by H. Pylori
- H. Pylori diminishes Iron Absorption from diet
- A number of meta-analyses confirmed the role of H. pylori eradication in improving **Iron Deficiency Anaemia** correction with appropriate Iron therapy



5. Physiological Blood Loss in Women


1 ml Blood = 0.5mg Elemental Iron

↓ In 1g/dL Hb \approx 200mg Loss in Elemental Iron

**Menorrhagia (>80ml/cycle) for 1 year →
> 500mg Loss in Elemental Iron / yr**

**Each Full Term Pregnancy Consumes
 \approx 900mg Elemental Iron (WHO)**

6. Improper Iron Supplement for Pregnancy

 **NIH Public Access**
Author Manuscript
Am J Med. Author manuscript; available in PMC 2009 November 1.

Published in final edited form as:
Am J Med. 2008 November ; 121(11): 943–948. doi:10.1016/j.amjmed.2008.07.012.

Individualized treatment for iron deficiency anemia in adults

Michael Alleyne, MD^{a,c}, McDonald K. Horne, MD^b, and Jeffery L. Miller, MD^{c,*}



Multivitamin preparations **should never be recommended** as a sole therapy for iron deficient anemia, since the **calcium**, **phosphorus** and **magnesium salts** contained in iron-containing multivitamin pills **impair absorption of elemental iron**.



MINERALS

Calcium (calcium carbonate)	250 mg
Magnesium (magnesium oxide)	50 mg
Iodine (potassium iodide)	0.15 mg
Iron (ferrous fumarate)	60 mg
Copper (cupric oxide)	2 mg
Zinc (zinc oxide)	25 mg
Chromium (chromium chloride)	25 mcg
Manganese (manganese sulfate)	5 mg
Molybdenum(sodium molybdate)	25 mcg
Selenium (sodium selenate)	25 mcg

THERAPEUTIC USE ONLY

7. Repeated Blood Donation

1 ml Blood = 0.5mg Elemental Iron

≈200mg Elemental Iron loss in Each Donation



Perpetuation of Iron Deficiency

Hospital Settings:

- Blood Transfusion as reflex response to treat Anaemia
- Pathological causes of Blood Loss managed
- Under-diagnosed Iron Deficiency in many chronic illness
e.g. Chronic Renal Impairment, Chronic Heart Failure, Malignancy, Inflammatory Conditions...
- Blood Loss due to various procedures and blood taking
- Insufficient treatment to minimize Blood Loss
- Underlying Iron Deficiency seldom received adequate treatment



GP/FM/SOPD Settings:

- Pathological causes of Blood Loss diagnosed and treated *or* referred to Hospital
- Underlying Iron Deficiency seldom received adequate treatment
- Insufficient treatment to control chronic Blood Loss (physiological or pathological)
- Anti-platelet or oral anti-coagulation therapy may increase Blood Loss
- Acid suppressants inhibit Iron Absorption



Iron Deficiency related to:

- Inadequate Iron Intake
- Suboptimal Iron Absorption
- Helicobacter Pylori Infection
- Physiological Blood Loss
- Suboptimal Iron Supplement during pregnancy
- Blood Donation
- Poor Compliance to Iron Therapy



8. Drug Interaction affecting Iron Absorption

Clinical Data Analysis & Reporting System

Patient-Based Analysis

Data Source in (User Defined Query: **Antacids, H2 Receptor Antagonists or PPIs**

Drug Dispensing Date Between 01/01/2017 and 31/12/2017)

Institution Cluster	No. of Patient Headcount
A	118594
B	81754
C	211878
D	152885
E	199999
F	179179
G	173743
Grand Total :	1,118,032

MEDICATIONS INHIBITING IRON ABSORPTION:

H2 receptor blockers, antacid medications, proton pump inhibitors; tetracyclines, quinolones; ACEI; levothyroxine; levodopa, carbidopa; cholestyramine and colestipol (bile acid sequestrant)

9. Anti-platelet or oral anticoagulant may increase bleeding

Clinical Data Analysis & Reporting System

Patient-Based Analysis

Data Source in (

« Drug{Therapeutic Classification (BNF, Principal or Secondary) in (

Drug BNF: **2.9 ANTIPLATELET DRUGS**

Drug BNF: **2.8.2 ORAL ANTICOAGULANTS**)} »

Drug Dispensing Date Between 01/01/2017 and 31/12/2017)

Institution Cluster	No. of Patient Headcount
A	47645
B	36526
C	79987
D	57526
E	74886
F	64914
G	50320
Grand Total :	411,804

Perpetuation of Iron Deficiency

Hospital Settings:

- Blood Transfusion as reflex response to treat Anaemia
- Pathological causes of Blood Loss managed
- Under-diagnosed Iron Deficiency in many chronic illness
e.g. Chronic Renal Impairment, Chronic Heart Failure, Malignancy, Inflammatory Conditions...
- Blood Loss due to various procedures and blood taking
- Insufficient treatment to minimize Blood Loss
- Underlying Iron Deficiency seldom received adequate treatment



GP/FM/SOPD Settings:

- Pathological causes of Blood Loss diagnosed and treated *or* referred to Hospital
- Underlying Iron Deficiency seldom received adequate treatment
- Insufficient treatment to control chronic Blood Loss (physiological or pathological)
- Anti-platelet or oral anti-coagulation therapy may increase Blood Loss
- Acid suppressants inhibit Iron Absorption



Iron Deficiency related to:

- Inadequate Iron Intake
- Suboptimal Iron Absorption
- Helicobacter Pylori Infection
- Physiological Blood Loss
- Suboptimal Iron Supplement during pregnancy
- Blood Donation
- Poor Compliance to Iron Therapy



10. Gastrointestinal Blood Loss



1 ml Blood = 0.5mg Elemental Iron

↓ 1g/dL Hb \approx 200mg Loss in Elemental Iron

11. GIB received Blood Transfusion in 2016: *Underlying Iron Deficiency is Insufficiently Treated*

	GI neoplasms	Non-malignant Lower GIB	Non-malignant Upper GIB
Number of unique patients	3,604	3,161	5,612
Median age (range)	72 (3~105)	78 (0~106)	75 (0~105)
Number of transfusion episodes	5,377	5,870	9,789
Units of RC transfused	9,179	10,262	16,558
Episodes			
• Pre-transfusion Hb absent	97 (1.8%)	14 (0.2%)	17 (0.2%)
• Post-transfusion Hb absent	909 (16.9%)	305 (5.2%)	497 (5.1%)
• Pre-transfusion Hb ≥ 8 g/dL	1,423 (26.5%)	1,429 (24.3%)	2,043 (20.9%)
• Post transfusion Hb ≥ 10 g/dL	1,626 (30.2%)	1,602 (27.3%)	2,379 (24.3%)
• Multiple units RC given	3,230 (60.1%)	3,521 (60.0%)	5,510 (56.3%)
Neither parenteral nor oral iron given	2,458 (68.2%)	2,352 (74.4%)	3,863 (68.8%)

1st Pillar

OPTIMIZE
HEMATOPOIESIS

Neither parenteral nor
oral iron in ~2/3

2nd Pillar

MINIMIZE
BLOOD LOSS

3rd Pillar

OPTIMIZE
PATIENT-SPECIFIC
TOLERANCE TO
ANAEMIA

Post transfusion Hb \geq
10 g/dL in 1/4 ~ 1/3

Multiple units RC given
in ~2/3

How often was iron deficiency managed in gastrointestinal bleeding?

Dr Ching-Wa LAU, Dr Jennifer Nga-Sze LEUNG, Dr Cheuk-Kwong LEE

Hong Kong Red Cross Blood Transfusion Service



Data from CDARDS

12. Gynecology Patients received Blood Transfusion in 2016: *Underlying Iron Deficiency is Insufficiently Treated* *Bleeding Condition is Insufficiently Managed*

Study Period between 01/01/2016 and 31/12/2016

Gynecology Patients Age ≤ 60 (range 11~60), Non-operation related Admission
(2,906 Transfusion Episodes of 5,889 units RC in 2,523 Unique Patients)

Pre-transfusion Hb	Median Age	1 unit RC	2 units RC	3 units RC	4 units RC	5 units RC	>5 units RC	Total Transfusion Episodes	Post-transfusion Hb <7	Post-transfusion Hb 7~8	Post-transfusion Hb 8~9	Post-transfusion Hb 9~10	Post-transfusion Hb >10	Post-transfusion Hb missing
< 7	45	77	777	525	77	3	2	1461	65	208	537	413	136	102
7~8	45	374	656	17	0	0	0	1047	4	52	287	411	179	114
8~9	45	148	117	1	0	0	0	266	3	8	43	76	85	51
9~10	44	23	16	0	0	0	0	39	0	1	4	8	21	5
≥ 10	36	10	7	0	0	0	0	17	1	1	0	3	12	0
Pre-transfusion Hb missing	46	16	50	10	0	0	0	76	0	7	17	26	15	11
Total	45	648	1623	553	77	3	2	2906	73	277	888	937	448	283

1st Pillar

**OPTIMIZE
HEMATOPOIESIS**

3.2% GIVEN TRANEXAMIC ACID ALONE @ DISCHARGE

15.0% GIVEN IRON ALONE @ DISCHARGE

65.8% GIVEN IRON + TRANEXAMIC ACID @ DISCHARGE

UP TO 16.0% NOT GIVEN IRON OR TRANEXAMIC ACID @ DISCHARGE

2nd Pillar

**MINIMIZE
BLOOD LOSS**

3rd Pillar

**OPTIMIZE
PATIENT-SPECIFIC
TOLERANCE TO
ANAEMIA**

**2/3 TRANSFUSED
WITH MULTIPLE UNITS**


**ALMOST ½ POST
TRANSFUSION
HB \geq 9G/DL**

**ALMOST 10% WITH NO
POST TRANSFUSION
HB CHECKED**

Gaps in Managing Gynaecological Patients with Iron Deficiency Anaemia

Ching-Wa Lau¹, Wing-Cheong Leung², Nga-Sze Leung¹ and Cheuk-Kwong Lee¹, (1)Hc Transfusion Service, Hong Kong, Hong Kong, (2)Kwong Wah Hospital, Hong Kong, Hong Kong

13. Anaemia Treatment in Hemodialysis: *Underlying Iron Deficiency is Insufficiently Treated*



	Hemodialysis Headcount	Percentage
No Treatment	683	15.9%
Transfusion Alone	1212	28.2%
EPO Alone	792	18.4%
IV Iron Alone	8	0.2%
EPO +IV Iron	147	3.4%
EPO+Transfusion	1248	29.0%
IV Iron+ Transfusion	16	0.4%
EPO+ IV Iron+ Transfusion	199	4.6%

N=4305

No Anaemia Treatment
15.9%

14. Operation

1 ml Blood = 0.5mg Elemental Iron
↓ 1g/dL Hb \approx 200mg Loss in Elemental Iron

Anaemia is present in up to 90% of patients in the immediate postoperative period after major surgery.

15. Obstetric Patients undergoing Cesarean Section in 2016/17: *Bleeding Condition is Insufficiently Managed*

Hospital Code in (All Hospitals) AND

Discharge Date between 01/10/2016 and 30/09/2017 AND

Diagnosis Code (ICD9) in (74 **CESAREAN SECTION** AND REMOVAL OF FETUS)

Use of IV Transamin	Yes	No	Row Total
Institution Cluster (Admission Date)	No. of Episodes Headcounts	No. of Episodes Headcounts	No. of Episodes Headcounts
A		872	872
B		966	966
C	19	2310	2329
D	5	903	908
E	43	1660	1703
F	13	1690	1703
G		1637	1637
Grand Total :	80	10038	10118

16. Obstetric Patients with PPH in 2016/17: *Bleeding Condition is Insufficiently Managed*

Hospital Code in (All Hospitals) AND

Discharge Date between 01/10/2016 and 30/09/2017 AND

Diagnosis Code (ICD9) in (666 **POSTPARTUM HEMORRHAGE**)

Use of IV Transamin	Yes	No	Row Total
Institution Cluster (Admission Date)	No. of Episodes Headcounts	No. of Episodes Headcounts	No. of Episodes Headcounts
A	3	183	185
B	2	232	234
C	51	526	574
D	11	431	442
E	16	499	513
F	5	384	389
G		306	306
Grand Total :	88	2553	2635

Perpetuation of Iron Deficiency

Hospital Settings:

- Blood Transfusion as reflex response to treat Anaemia
- Pathological causes of Blood Loss managed
- Under-diagnosed Iron Deficiency in many chronic illness e.g. Chronic Renal Impairment, Chronic Heart Failure, Malignancy, Inflammatory Conditions...
- Blood Loss due to various procedures and blood taking
- Insufficient treatment to minimize Blood Loss
- Underlying Iron Deficiency seldom received adequate treatment



GP/FM/SOPD Settings:

- Pathological causes of Blood Loss diagnosed and treated or referred to Hospital
- Underlying Iron Deficiency seldom received adequate treatment
- Insufficient treatment to control chronic Blood Loss (physiological or pathological)
- Anti-platelet or oral anti-coagulation therapy may increase Blood Loss
- Acid suppressants inhibit Iron Absorption



Iron Deficiency related to:

- Inadequate Iron Intake
- Suboptimal Iron Absorption
- Helicobacter Pylori Infection
- Physiological Blood Loss
- Suboptimal Iron Supplement during pregnancy
- Blood Donation
- Poor Compliance to Iron Therapy



Diagnosis


WHO Definitions of Anaemia in Adult			
(gm/dl)	Mild	Moderate	Severe
Pregnant women	10.0-10.9	7.0-9.9	<7
Non-pregnant women	11-11.9	8.0-10.9	<8
Men	11.0-12.9	8.0-10.9	<8

WHO Definitions of Iron Deficiency	Most global experts Definitions of Iron Deficiency
<15 ng/ml	<30 ng/ml
	Sensitivity 92%
	Positive predictive value 83%
Ferritin 1ng/ml \approx 8mg Iron Store	

TRANSFUSION ALTERNATIVES

1. Maximizing endogenous red cell production by **TRANSFUSION ALTERNATIVES**
2. Minimizing endogenous red cell loss by **TRANSFUSION ALTERNATIVES** and good surgical and anesthetic techniques
3. Safe and appropriate use of **ALLOGENEIC BLOOD TRANSFUSION** to improve patient clinical outcomes, not the number


Clinical Scenarios in which Benefits of Transfusion out-weight the Risks



- Blood Loss (Gynecology 4%, GIB 20%, Elective operations 13%, Emergency operations 8%, Trauma 5%)
- Renal Insufficiency (Hemodialysis 7%, peritoneal dialysis and non-dialysis 7%)
- Marrow Failure 10%, Red Cell Disorders 6%, Hematological Malignancy 10%, some Oncological conditions 10%

**Allogeneic red cell metabolized in a few weeks,
the only thing left inside the patient is
no more than 200mg of Elemental Iron**

Every Unit of Red Cell \approx 200mg Elemental Iron



GLOBAL BENCHMARK

Red Cell Use per 1,000 Population

